Ophthalmology. Retina最新文献

{"title":"Potential 20-Week Faricimab Dosing in Wet Age-Related Macular Degeneration.","authors":"Aude Ambresin, Varun Chaudhary, Richard Gale, Adrian Hock Chuan Koh, Nikolas J S London, Praveen J Patel, Anna C S Tan, Lauren Hill, Aachal Kotecha, Philippe Margaron, Michael Singer","doi":"10.1016/j.oret.2026.02.001","DOIUrl":"10.1016/j.oret.2026.02.001","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes.","authors":"Alexander T Hong, Forest Lin, Jeremy D Keenan, Jay M Stewart","doi":"10.1016/j.oret.2026.02.002","DOIUrl":"10.1016/j.oret.2026.02.002","url":null,"abstract":"<p><strong>Objective: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown both protective and adverse effects on ocular outcomes. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, achieves greater glycemic and cardiometabolic improvements than non-GIP agonistic GLP-1 RAs, yet its ocular safety profile remains poorly characterized.</p><p><strong>Purpose: </strong>To compare the risk of retinal complications in patients with type 2 diabetes (T2D) treated with tirzepatide versus non-GIP GLP-1 RAs.</p><p><strong>Design: </strong>A retrospective cohort study analyzed a nationwide electronic health records network from June 2022 to June 2025.</p><p><strong>Participants: </strong>Adults with T2D initiating tirzepatide or a non-GIP GLP-1 RA, with no prior use of either drug class. Individuals who initiated any other second-line glucose-lowering therapies within 6 months before or during the study period were excluded to isolate the effect of the medication.</p><p><strong>Methods: </strong>A cohort of patients initiating therapy with tirzepatide was compared with another cohort initiating a non-GIP GLP-1 RA. Hazard ratios (HRs) for several ocular outcomes over a 36-month follow-up period were calculated, using propensity score-matched cohorts (1:1) to address confounding from demographics, comorbidities, and medication use. Similar analyses were performed among subpopulations of metformin or insulin users at cohort entry and among those who initiated additional antihyperglycemic therapy after index prescription.</p><p><strong>Main outcome measures: </strong>Risk of diabetic retinopathy (DR), diabetic macular edema (DME), vitreous hemorrhage (VH)/retinal detachment (RD), need for vision-saving interventions (intravitreal injections, panretinal photocoagulation, or pars plana vitrectomy), and nonarteritic anterior ischemic optic neuropathy (NAION).</p><p><strong>Results: </strong>After matching, each cohort included 102 590 patients. Tirzepatide use was associated with decreased risk of DR (HR, 0.79; 95% confidence interval [CI], 0.72-0.87), DME (HR, 0.82; 95% CI, 0.68-0.96), VH/RD (HR, 066; 95% CI, 0.45-0.95), DR-related vision-saving interventions (HR, 0.65; 95% CI, 0.49-0.88), and NAION (HR, 0.45; 95% CI, 0.27-0.86) compared with non-GIP GLP-1 RA use. Associations were consistent among metformin and insulin users and in those who initiated additional antihyperglycemic therapy during follow-up.</p><p><strong>Conclusions: </strong>Among patients with T2D taking a GLP-1 RA, tirzepatide was associated with lower risks of retinal complications, need for vision-saving interventions, and NAION compared with GLP-1 RAs without GIP activity. These findings support a favorable ocular safety profile for tirzepatide, though confirmation in prospective studies is warranted.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Patent Primary Hyaloidal Vessel.","authors":"Sagarika Snehi, Anusua Kar, Kanishk Singh, Rajesh Pattebahadur","doi":"10.1016/j.oret.2026.01.008","DOIUrl":"https://doi.org/10.1016/j.oret.2026.01.008","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Trial of Biosimilar ABP 938 Compared with Reference Aflibercept in Adults with Neovascular Age-Related Macular Degeneration","authors":"Scott Friedman MD ,&nbsp;Nikolas London MD ,&nbsp;Jan Hamouz MD ,&nbsp;Ágnes Kerényi MD ,&nbsp;Andras Papp MD, PhD ,&nbsp;Tamás Pregun MD ,&nbsp;Vincent Chow PhD ,&nbsp;Bianca Bautista PhD ,&nbsp;Daidong Wang MS ,&nbsp;Gary Grachev MD, PhD ,&nbsp;Janet Franklin MD","doi":"10.1016/j.oret.2025.07.015","DOIUrl":"10.1016/j.oret.2025.07.015","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the clinical efficacy, safety, and immunogenicity of biosimilar ABP 938 compared with the aflibercept reference product (RP) in adults with neovascular (wet) age-related macular degeneration (nAMD).</div></div><div><h3>Design</h3><div>A randomized, double-masked, active-controlled, multiregional clinical study.</div></div><div><h3>Participants</h3><div>A total of 579 patients with active treatment-naïve choroidal neovascularization secondary to nAMD were randomized.</div></div><div><h3>Methods</h3><div>Evaluable patients (N = 576) received 2 mg of ABP 938 (n = 288) or aflibercept RP (n = 288) by intravitreal injection every 4 weeks for the first 3 doses, then every 8 weeks through week 48. At week 16, the ABP 938 group continued on ABP 938 (n = 273), whereas the aflibercept RP group was rerandomized to continue on aflibercept RP (n = 136) or transition to ABP 938 (n = 134).</div></div><div><h3>Main Outcome Measures</h3><div>The primary efficacy end point was the least squares (LS) mean difference in change in best-corrected visual acuity (BCVA), measured by ETDRS letter score, from baseline to week 8. Secondary efficacy end points, safety, and immunogenicity were analyzed descriptively. In a substudy of patients, serum drug concentration profiles were assessed.</div></div><div><h3>Results</h3><div>Demographic and baseline characteristics and exposure to treatment were similar between groups. Among initially randomized patients, the LS mean difference in change from baseline in BCVA at week 8 between ABP 938 and aflibercept RP was 0.1, with a 2-sided 95% confidence interval (CI: –1.3, 1.5) and 90% CI (–1.1, 1.3) falling within prespecified similarity margins (–3.9, 3.9, and –3, 3, respectively); thus, the primary clinical efficacy end point was met. Secondary efficacy end points (parallel-arm and posttransition) were overall similar between groups. No clinically meaningful differences were observed in the incidence of ocular and nonocular adverse events or events of interest. A low and similar incidence of binding antidrug antibodies was observed in all groups. The substudy confirmed low systemic exposure of free drug concentrations of ABP 938 and aflibercept RP.</div></div><div><h3>Conclusions</h3><div>This study supports the conclusion of no clinically meaningful differences in efficacy, safety, and immunogenicity between ABP 938 and aflibercept RP in patients with nAMD. Additionally, transitioning from aflibercept RP to APB 938 at week 16 resulted in comparable efficacy, safety, and immunogenicity between treatment groups.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 2","pages":"Pages 152-164"},"PeriodicalIF":5.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association between Retinal Vascular Occlusions and Dementia","authors":"Audrey Gao BA ,&nbsp;Fatima Tuz-Zahra MS ,&nbsp;Viha Vig MBChB ,&nbsp;Rebecca Zeng MD ,&nbsp;Yorghos Tripodis PhD ,&nbsp;Thor D. Stein MD, PhD ,&nbsp;Michael L. Alosco PhD ,&nbsp;Steven Ness MD ,&nbsp;Xuejing Chen MD ,&nbsp;Nicole Siegel MD ,&nbsp;Manju L. Subramanian MD","doi":"10.1016/j.oret.2025.08.010","DOIUrl":"10.1016/j.oret.2025.08.010","url":null,"abstract":"<div><h3>Purpose</h3><div>Vascular disease is associated with increased incidence of dementia and has the potential to be an indicator of underlying cognitive disease. The goal of this study is to investigate the association between retinal vascular occlusions and neurodegenerative disorders that lead to dementia, including all-cause dementia, Alzheimer disease (AD), and vascular dementia (VD).</div></div><div><h3>Design</h3><div>Retrospective longitudinal cohort study.</div></div><div><h3>Participants</h3><div>This study consists of 502 133 participants from the UK Biobank, aged 40 to 69 years at recruitment. There are 1463 individuals with retinal vascular occlusion and 500 670 individuals without.</div></div><div><h3>Methods</h3><div>Individuals were categorized as having retinal vein occlusion (RVO), retinal artery occlusion (RAO), and any retinal vascular occlusion (both RVO and RAO). Prevalence and incidence of all-cause dementia, AD, and VD were calculated. The patients with RVO were then matched on age, sex, education, and employment score on a 1:3 ratio to controls. Univariate and multivariate Cox proportional hazards models on the matched participants were used to determine associations over time to all-cause dementia, AD, and VD, with added adjustments for diabetes, hypertension, and smoking status.</div></div><div><h3>Main Outcome Measures</h3><div>Prevalence and hazard ratios (HRs) of all-cause dementia, AD, and VD.</div></div><div><h3>Results</h3><div>The prevalence of all-cause dementia and AD is significantly increased among patients with RVO, RAO, and any retinal vascular occlusion, whereas the prevalence of VD is significantly increased in RVO and any retinal vascular occlusion. In the matched analysis, increased risk for all-cause dementia was seen in patients with any retinal vascular occlusion (HR, 1.52; confidence interval [CI], 1.11–2.07, <em>P</em> = 0.01) and RVO (HR, 1.38; CI, 1.01–1.90, <em>P</em> = 0.04). When adjusting for covariates, RVO did not show increased risk of all-cause dementia, AD, and VD.</div></div><div><h3>Conclusions</h3><div>Any retinal vascular occlusions and RVO are associated with increased risk of all-cause dementia, and individuals with RVO also have higher risk of VD. After adjusting for shared risk factors, there is no association between dementia and retinal vascular occlusions. Findings from this study are both consistent and in conflict with prior reports, and indicate that the connection between retinal vascular occlusions and neurodegenerative diseases causing dementia may be due to their shared pathogenesis and risk factors.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 2","pages":"Pages 128-134"},"PeriodicalIF":5.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144874327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noninvasive Synthesis of Multiframe Ultra-Widefield Fluorescein Angiography from Color Fundus Photographs","authors":"Ruoyu Chen MD ,&nbsp;Kezheng Xu MD ,&nbsp;Kangyan Zheng MD ,&nbsp;Weiyi Zhang MS ,&nbsp;Yan Lu MD, PhD ,&nbsp;Mingguang He MD, PhD ,&nbsp;Danli Shi MD, PhD","doi":"10.1016/j.oret.2025.08.002","DOIUrl":"10.1016/j.oret.2025.08.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To generate dye-free ultra-widefield fluorescein angiography (UWF-FA) images from noninvasive ultra-widefield color fundus photography (UWF-CFP) using generative artificial intelligence (AI) and to evaluate its effectiveness in diabetic retinopathy (DR) screening.</div></div><div><h3>Design</h3><div>A cross-sectional study involving generative AI.</div></div><div><h3>Participants</h3><div>This study included 1263 patients with DR (2747 UWF-CFP images and 18 321 UWF-FA images) from the Second People's Hospital of Foshan.</div></div><div><h3>Methods</h3><div>Ultra-widefield CFP and UWF-FA image pairs were matched and used to train a pix2pixHD generative adversarial network (GAN)-based model modified with Gradient Variance Loss. The generated UWF-FA images were evaluated using quantitative similarity metrics and qualitative ophthalmologist evaluation. An external data set, DeepDRiD, was used to validate the contribution of the generated UWF-FA images to DR grading.</div></div><div><h3>Main Outcome Measures</h3><div>The area under the receiver operating characteristic curve for DR grading.</div></div><div><h3>Results</h3><div>The generated early-, mid-, and late-phase UWF-FA images demonstrated high authenticity, with multiscale similarity scores ranging from 0.70 to 0.91 and qualitative evaluation scores from 1.64 to 1.98 (1 = real UWF-FA quality). In a Turing test with 50 randomly selected images, 56% to 76% of the generated images were indistinguishable from real images. Generated UWF-FA images successfully depict details of DR lesions, such as a nonperfusion area and leakage. The incorporation of these generated UWF-FA images in DR grading significantly improved the area under the receiver operating characteristic curve from 0.869 to 0.904 compared with the baseline model using UWF-CFP images alone (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The study suggests that the GAN-based model can successfully generate realistic multiframe UWF-FA images, which could enhance DR grading without the need for IV dye injection, with the potential to improve the safety and accessibility of DR screening.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 2","pages":"Pages 176-184"},"PeriodicalIF":5.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Artery-Retinal Vein Anastomosis in Juxtapapillary Retinal Capillary Hemangioma","authors":"Gongpeng Sun MD ,&nbsp;Meixia Zhang MD, PhD","doi":"10.1016/j.oret.2025.05.022","DOIUrl":"10.1016/j.oret.2025.05.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 2","pages":"Page e12"},"PeriodicalIF":5.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Link between Retinal Vascular Occlusion and Dementia","authors":"Hemal Patel MD,&nbsp;Sharon Fekrat MD, FASRS","doi":"10.1016/j.oret.2025.11.005","DOIUrl":"10.1016/j.oret.2025.11.005","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 2","pages":"Pages 115-116"},"PeriodicalIF":5.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146098467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Retained Perfluoro-n-Octane Not Impacting Patient’s Vision","authors":"Normila Barthelemy MD ,&nbsp;Maura Abraham MD ,&nbsp;Zelia M. Correa MD, PhD","doi":"10.1016/j.oret.2025.06.001","DOIUrl":"10.1016/j.oret.2025.06.001","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 2","pages":"Page e16"},"PeriodicalIF":5.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Alzheimer Disease and Related Dementia after Retinal Vascular Occlusion","authors":"Hou-Ren Tsai MD ,&nbsp;Yu-Jie Lin MSc ,&nbsp;Ching-Hui Loh DrPH ,&nbsp;Yuan-Chieh Lee PhD ,&nbsp;Huei-Kai Huang PhD","doi":"10.1016/j.oret.2025.10.017","DOIUrl":"10.1016/j.oret.2025.10.017","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the risk of developing Alzheimer disease (AD) and related dementia in patients with newly diagnosed retinal vascular occlusion.</div></div><div><h3>Design</h3><div>A nationwide population-based cohort study using claims data from Taiwan’s National Health Insurance Research Database (NHIRD).</div></div><div><h3>Participants and Controls</h3><div>A total of 39 540 individuals with diagnoses of retinal vascular occlusion between 2011 and 2019 in Taiwan and 395 400 age- and sex-matched nonretinal vascular occlusion individuals without prior diagnoses of any dementia.</div></div><div><h3>Methods</h3><div>Patients with newly diagnosed retinal vascular occlusion were identified in the NHIRD, and baseline characteristics were collected. The study endpoints, including AD, vascular dementia (VD), and all-cause dementia, were determined by ≥2 separate outpatient diagnoses or a single discharge diagnosis. Inverse probability of treatment weighting (IPTW) was applied to balance baseline covariates and control potential confounders. Cox proportional hazards models were used to estimate the hazard ratio (HR) for each outcome.</div></div><div><h3>Main Outcome Measures</h3><div>Development of AD, VD, and all-cause dementia.</div></div><div><h3>Results</h3><div>After IPTW, 38 522 patients with retinal vascular occlusion and 395 740 nonretinal vascular occlusion individuals were included. Patients with retinal vascular occlusion had increased risks of AD (HR, 1.57; 95% confidence interval [CI], 1.39–1.80), VD (HR, 1.76; 95% CI, 1.58–1.95), and all-cause dementia (HR, 1.58; 95% CI, 1.50–1.65). Both retinal artery occlusion and retinal vein occlusion were associated with increased risks of AD (HR, 1.59; 95% CI, 1.14–2.23; and HR, 1.58; 95% CI, 1.39–1.80, respectively), VD (HR, 1.79; 95% CI, 1.32–2.43; and HR, 1.77; 95% CI, 1.59–1.98, respectively), and all-cause dementia (HR, 1.62; 95% CI, 1.42–1.86; and HR, 1.58; 95% CI, 1.52–1.67, respectively).</div></div><div><h3>Conclusions</h3><div>Patients with retinal vascular occlusion had moderately increased risks of AD and related dementias. Therefore, monitoring for dementia symptoms in patients with retinal vascular occlusion may facilitate earlier detection and intervention.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 2","pages":"Pages 117-127"},"PeriodicalIF":5.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}